medigraphic.com
ISSN 2520-9078 (Electronic)

2022, Number 2

<< Back Next >>

Revista de Ciencias Médicas de la Habana 2022; 29 (2)

COVID-19 therapeutics based on the structure of SARS-CoV-2

González BSN, Feria DGE, Expósito LA, Miguel SPE

Language: Spanish
References: 48
Page: 265-286
PDF size: 814.08 Kb.


ABSTRACT

Introduction: Knowledge of the structure and the molecular biology of SARS-CoV-2, is important for the design and application of medications against COVID-19.
Objective: To describe the therapeutics of COVID-19, based on the structure of SARS-CoV-2.
Methods: An integrated, non-systematic revision, with the descriptors from DeCS Google Scholar, The Lancet, PubMed Central and SciELO, was performed using articles in Spanish and English, published in 2020 and 2021.
Conclusions: Among the medications for COVID-19, based on the structure of SARS-CoV-2, there are monoclonal antibodies, inhibitors of the fusion of protease, the viral replication and vaccines. The main used antibodies are: bamlanivimab, etesevimab, casirivimab, imdevimab and meplazumab; among the inhibitors: remdesivir, favipiravir, lopinavir, umifenovir, camastat and péptids (EK1, EK1C4 y HD5). The vaccine platforms use protein sub-units, which are particles similar to a virus, viral vectors, nucleic acids and inactive or attenuated virus.


REFERENCES

  1. Jiang HDC, Tao YY, Jia SY, Li JX, Zhu FC. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl) [Internet]. 2021[citado 17 Abr 2022]; 134(17): 2037–44. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440017/pdf/cm9-134-2037.pdf

  2. World Health Organization[Internet]. Ginebra: WHO; c 2022. [actualizado 15 Jun 2022; citado 1 Oct 2021]. Disponible en: https://covid19.who.int

  3. Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev[Internet]. 2021[citado 17 Abr 2022];170:1-25. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759095/pdf/main.pdf

  4. Ehianeta T, Mzee SAS, Adebisi MK, EhianetaO. Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. Infectious Microbes &D iseases[Internet]. 2021[citado 17 Abr 2022];3(3): 125–33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454280/pdf/im9-3-125.pdf

  5. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews. 2021; 19: 141- 54. doi: https://doi.org/10.1038/s41579-020-00459-7

  6. Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Rev Vaccines. 2021; 20(1):1–22. doi: https://doi.org/10.1080/14760584.2021.1875824

  7. Altawalah H. Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines (Basel). 2021; 9(8): 910. doi: https://doi.org/10.3390/vaccines9080910

  8. Anand U, Jakhmola S, Indari O, Jha HC, Chen Z-S, Tripathi V, Pérez de la Lastra JM. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Front Immunol[Internet]. 2021[citado 17 Abr 2022]; 12:658519. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278575/pdf/fimmu-12-658519.pdf

  9. Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, et al. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduct Target Ther. 2021;6: 317.doi: https://doi.org/10.1038/s41392-021-00733-x

  10. Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell MolImmunol. 2021; 8:2293 – 306. doi: https://doi.org/10.1038/s41423-021-00752-2

  11. Shahzamani K, Mahmoudian F, Ahangarzadeh S, Ranjbar MM, Beikmohammadi L, Bahrami S, et al. Vaccine design and delivery approaches for COVID-19. IntImmuno Pharmacol. 2021; 100: 108086. doi: https://doi.org/10.1016/j.intimp.2021.108086

  12. Castro Dopico X, Ols S, Loré K, Hedestam GBK. Immunity to SARS‐CoV‐2 induced by infection or vaccination. J Intern Med[Internet]. 2021[citado 17 Abr 2022];00:1–19. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447342/pdf/JOIM-9999-0.pdf

  13. Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, et al. A Comprehensive review of Viral characteristics, transmission, pathophysiology, immune Response, and managementof SARS-CoV-2 and COVID-19 as a Basis for controlling the pandemic. Front Immunol[Internet]. 2021[citado 17 Abr 2022];12:631139. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952616/pdf/fimmu-12-631139.pdf

  14. Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliv Rev[Internet].2021[citado 17 Abr 2022];170:113–41. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789827/pdf/main.pdf

  15. Lozada-Requena I y Núñez Ponce C. COVID-19: respuesta inmune y perspectivas terapéuticas. Revista Peruana de Medicina Experimental y Salud Pública [Internet]. 2020 [citado 17 Abr 2022];37 (2): 312-9. Disponible en: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5490/3723

  16. De P, Chakraborty I, Karna B, Mazumder N. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. Eur J Pharmacol[Internet]. 2021[citado 17 Abr 2022];898:173977. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905377/

  17. Sharma A, Ahmad Farouk I, Lal SK. COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. Viruses[Internet]. 2021[citado 17 Abr 2022];13(2):202. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911532/pdf/viruses-13-00202.pdf

  18. Raskin S. Genetics of COVID-19. J Pediatr (Rio J). [Internet]. 2021[citado 17 Abr 2022]; 97 (4): 378-86. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539923/

  19. Jia Z, Gong W. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines? J Korean Med Sci[Internet]. 2021[citado 17 Abr 2022];36(18):e124. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111046/pdf/jkms-36-e124.pdf

  20. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Resendiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol[Internet]. 2021[citado 17 Abr 2022];12:701501. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311925/pdf/fimmu-12-701501.pdf

  21. Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B[Internet]. 2021[citado 17 Abr 2022];2:[aprox. 6 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260826/pdf/main.pdf

  22. Krumm ZA, Lloyd GM, Francis CP, Nasif LH, Mitchell DA, Todd E. Golde, et al. Precision therapeutic targets for COVID-19. Virol J. 2021;18: 66. doi: https://doi.org/10.1186/s12985-021-01526-y

  23. Gouvêa dos Santos W. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother[Internet]. 2021[citado 17 Abri 2022]; 136: 111272.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802525/pdf/main.pdf

  24. Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, Łos MJ. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020; 53:100719. doi: https://doi.org/10.1016/j.drup.2020.100719

  25. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity[Internet]. 2021[citado 17 Abr 2022];54(8): 1636–51. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328682/pdf/main.pdf

  26. Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J[Internet]. 2021[citado 17 Abr 2022];23(1): 14. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784226/pdf/12248_2020_Article_532.pdf

  27. Beeraka NM, Tulimilli SV, Karnik M, Sadhu SP, Pragada RR, Aliev G, et al. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). Biomed Res Int[Internet]. 2021[citado 17 Abr 2022]; 2021:8160860. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168478/pdf/BMRI2021-8160860.pdf

  28. Wang M-Y, Zhao R,Gao L-J, Gao X-F, Wang D-P, Cao J-M. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol[Internet]. 2020[citado 17 Abr 2022];10:587269. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723891/

  29. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol[Internet]. 2021[citado 17 Abr 2022];21:382–93. Disponible en: https://doi.org/10.1038/s41577-021-00542-x

  30. Pashaei M, Rezaei N. Immunotherapy for SARS-CoV-2: potential opportunities, Expert Opinion on Biological Therapy[Internet]. 2020[citado 17 Abr 2022]; 20:10: 1111-6. Disponible en: https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1807933

  31. Zuo L, Ao G, Wang Y, Gao M, Qi X. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: a systematic review and meta-analysis. Journal of Infection[Internet]. 2021[citado 17 Abr 2022];84(2):20. Disponible en: https://www.journalofinfection.com/action/showPdf?pii=S01634453%2821%2900477-1

  32. Kuritzkes DR. Bamlanivimab for Prevention of COVID-19. JAMA[Internet]. 2021[citado 17 Abr 2022];326(1):31-2. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2780873

  33. Cohen MS, Nirula A, Mulligan M, Novak R, Marovich M, Stemer A, et al. Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. Topics in Antiviral Medicine[Internet]. 2021[citado 17 Abr 2022];29(1):32-3. Disponible en: https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-1250038

  34. U.S. Food and Drug Administration (FDA) [Internet]. Washington, D.C: U.S. Department of Health and Human Services c 2022. [; actualizado17 Abr 2022; citado 29 Sep 2021]. Disponible en: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

  35. Sherchan R, Cannady, Jr P. Casirivimab. 2021 Jun 21. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34283490

  36. Ruckmani A, Ilamathi K, Kumar R A, Kumar PU. COVID-19: A Review of Clinical Trials and Repurposed Drugs. Int J Nutr Pharmacol Neurol Dis [Internet].2021 [citado 17 Abr 2022];11:27-40. Disponible en: https://www.ijnpnd.com/article.asp?issn=2231-0738;year=2021;volume=11;issue=1;spage=27;epage=40;aulast=Ruckmani

  37. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. Biomed Pharmacother[Internet]. 2021[citado 17 Abr 2022];137:111330. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843108/pdf/main.pdf

  38. Younis NK, Zareef RO, Fakhri G, Bitar F, Eid AH, Arabi M. COVID-19: potential therapeutics for pediatric patients. PharmacolRep[Internet]. 2021. [citado 17 Abr 2022];73: 1520–38. Disponible en: https://link.springer.com/article/10.1007/s43440-021-00316-1

  39. Chilamakuri R, Agarwal S. COVID-19: Characteristics and therapeutics. Cells. 2021 ;10(2): 206. doi: https://doi.org/10.3390/cells10020206

  40. Solís Sánchez M. Revisión sistemática de inmunopatogenia y vacunas Covid-19 (SARS-CoV-2): PCR, respuesta inmunitaria, vacunas. Química Central. 2021;7(1):56–83. doi: https://doi.org/10.29166/quimica.v7i1.2914

  41. World Health Organization[Internet]. Ginebra WHO; 2021 Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Guidance Document 29 September 2021. [citado 17 Abr 2022]. Disponible en: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_29Sept2021_0.pdf

  42. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Current Opinion in Immunology. 2021;71:111–6. Disponible en: https://doi.org/10.1016/j.coi.2021.07.003

  43. Shaukat A, Hussain K, Shehzadi N. Vacunas contra la COVID-19: desarrollo, estrategias, tipos y reticencia al uso de la vacunación. Vacci Monitor[Internet]. 2021[citado 17 Abr 2022]; 30(3): 145-2. Disponible en: https://vaccimonitor.finlay.edu.cu/index.php/vaccimonitor/article/view/279

  44. Forni G, Mantovani A, Moretta L, Rappuoli R, Rezza G, Bagnasco A, et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ[Internet]. 2021[citado 17 Abr 2022];28(2): 626–39. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818063/

  45. Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Vaccines for COVID-19: Where do we stand in 2021? Paediatric Respiratory Reviews. 2021;39: 22-31. doi: https://doi.org/10.1016/j.prrv.2021.07.001

  46. Mehmood I, Ijaz M, Ahmad S, Ahmed T, Bari A, Abro A, et al. SARS-CoV-2: an update on genomics, risk assessment, potential therapeutics and vaccine development. Int J Environ Res Public Health[Internet]. 2021 [citado 17 Abr 2022];18(4): 1626. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915969/pdf/ijerph-18-01626.pdf

  47. Fathizadeh H, Afshar S, Masoudi MR, Gholizadeh P, Asgharzadeh M, Ganbarov K, et al. SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. Int J Biol Macromol[Internet]. 2021 [citado 17 Abr 2022];188: 740–50. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364403/pdf/main.pdf

  48. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med[Internet]. 2021[citado 17 Abr 2022];19: 173.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315897/




2020     |     www.medigraphic.com